Hyderabad-based Aurobindo Pharma is significantly increasing its investment in biologics manufacturing and biosimilars, marking a strategic shift beyond traditional generics. Its dedicated biologics arm, CuraTeQ Biologics, now boasts a robust pipeline of 15 products.
Targeting High-Demand Therapies
The expanded pipeline focuses on critical therapeutic areas: oncology, immunology, and respiratory therapies. Aurobindo anticipates numerous global biologic drugs, each generating substantial annual sales, will lose patent protection between 2028 and 2035. This creates a significant market opportunity for biosimilar manufacturers like CuraTeQ.
CuraTeQ Biologics has already secured product approvals in Europe, the UK, and Canada. Plans are underway to file Denosumab and Omalizumab biosimilars with European regulators this year, with subsequent filings expected in the US market. By 2030, Aurobindo projects CuraTeQ will have seven to eight marketed products across Europe, the UK, and Canada, alongside preparations for the US.
Expanding Contract Manufacturing and European Growth
Beyond its own pipeline, Aurobindo is also bolstering its biologics contract manufacturing (CDMO) capabilities through TheraNym. The company is commissioning a 60 kL mammalian cell culture facility by late 2026 and is planning a second biologics facility in collaboration with MSD, involving an estimated capital expenditure of $150-175 million. The global biologics CDMO market is experiencing over 12% annual growth, driven by pharmaceutical companies outsourcing complex manufacturing.
In parallel, Aurobindo's European formulations business achieved a significant milestone, surpassing €1 billion in revenue for FY26. Revenue from Europe surged by 30.2% year-on-year in the March quarter, contributing 31.6% to the company's consolidated revenue. K Nithyananda Reddy, Vice-Chairman and Managing Director, attributed these positive results to consistent volumes, improved operating efficiencies, and disciplined execution, with capacity expansions expected to sustain future growth.